Everything below concerns Pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
=== Stimulators === Decreased serum [Ca2+]. Mild decreases in serum [Mg2+]. An increase in serum phosphate (increased phosphate causes it to complex with serum calcium, forming calcium phosphate, which reduces stimulation of Ca-sensitive receptors (CaSr) that do not sense calcium phosphate, triggering an increase in PTH). Adrenaline Histamine
In America, in 2008, "next-generation" counting and verification systems were introduced. Based on the counting technology employed in preceding models, later machines included the ability to help the pharmacy operate more effectively. Equipped with a new computer interface to a pharmacy management system, with workflow and inventory software. It also included "checks and balances" to ensure the technician and pharmacist were dispensing the correct medication for each patient. This is something that is important to keep reported correctly when dealing with controlled substances like narcotics. This was a step forward to verify all 100% of prescriptions that were dispensed by pharmacy staff.
=== Using a metal and cyclopentadiene === This technique provides using metal atoms in the gas phase rather than the solid metal. The highly reactive atoms or molecules are generated at a high temperature under vacuum and brought together with chosen reactants on a cold surface.
Diabetes, Obesity and Metabolism is a monthly peer-reviewed medical journal established in 1999 covering research on diabetes, obesity, and metabolism. The journal has a 2024 Clarivate impact factor of 5.7. The journal publishes on topics such as pharmacokinetics and pharmacodynamics, cost-effectiveness, real world evidence of drug utilisation, safety and effectiveness, as well as conventional randomized controlled trials (phase I-IV studies).
Sources: en.wikipedia.org
=== History === Cornish-Bowden, Athel (1997). New Beer in an Old Bottle. Eduard Buchner and the Growth of Biochemical Knowledge. Valencia: Universitat de Valencia. ISBN 978-84-370-3328-0. Archived from the original on 13 December 2010. Retrieved 8 December 2007., A history of early enzymology. Williams, Henry Smith (1904). Modern Development of the Chemical and Biological Sciences. A History of Science: in Five Volumes. Vol. IV. New York: Harper and Brothers. Archived from the original on 9 May 2012. Retrieved 8 December 2007., a textbook from the 19th century.
==== 2016: Redshirt season ==== Following his matriculation at the University of Oregon in the spring of 2016, McCormick redshirted his freshman season while recovering from his knee injury. By August 2016, McCormick had been cleared to fully participate in football activities, though he was required to wear a knee brace. In September 2016, McCormick told The Oregonian that the brace may be blunting his speed, owing to the brace's impact on his natural running motion.
== Archaic Hassuna == ‘Archaic Hassuna’ has been introduced more recently as a new period different to proto-Hassuna. This period is recorded to have a decrease in the concentration of dung in ceramic production and an increase in the use of two-layer slabs in construction, although they were used prior to this period. During this timeframe, pottery kilns start to show up in many sites. The changing patterns within pottery may also connect with an increase in cultural diffusion. The type site, Tell Hassuna, is also recorded to possess Archaic Hassuna artifacts. The time frame for this period was about 6300-6000 BC.
=== Conductive ink === In 2012 Vorbeck Materials started shipping the Siren anti-theft packaging device, which uses their graphene-based Vor-Ink circuitry to replace the metal antenna and external wiring to an RFID chip. This was the world's first commercially available product based on graphene.
The Group Experiment, which had been unavailable to English readers, is now available in an accessible translation by Jeffrey K. Olick and Andrew J. Perrin on Harvard University Press, along with introductory material explaining its relation to the rest of Adorno's work and 20th-century public opinion research.
Sources: en.wikipedia.org
== Clinical significance == In addition to their roles in cancer development and chemotherapeutic drug resistance, GSTs are implicated in a variety of diseases by virtue of their involvement with GSH. Although the evidence is minimal for the influence of GST polymorphisms of the alpha, mu, pi, and theta classes on susceptibility to various types of cancer, numerous studies have implicated such genotypic variations in asthma, atherosclerosis, allergies, and other inflammatory diseases. Because diabetes is a disease that involves oxidative damage, and GSH metabolism is dysfunctional in diabetic patients, GSTs may represent a potential target for diabetic drug treatment. In addition, insulin administration is known to result in increased GST gene expression through the PI3K/AKT/mTOR pathway and reduced intracellular oxidative stress, while glucagon decreases such gene expression. Omega-class GST (GSTO) genes, in particular, are associated with neurological diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis; again, oxidative stress is believed to be the culprit, with decreased GSTO gene expression resulting in a lowered age of onset for the diseases.
=== Membrane proteins === Multi-monoubiquitylation can mark transmembrane proteins (for example, receptors) for removal from membranes (internalisation) and fulfil several signalling roles within the cell. When cell-surface transmembrane molecules are tagged with ubiquitin, the subcellular localization of the protein is altered, often targeting the protein for destruction in lysosomes. This serves as a negative feedback mechanism, because often the stimulation of receptors by ligands increases their rate of ubiquitylation and internalisation. Like monoubiquitylation, lysine 63-linked polyubiquitin chains also has a role in the trafficking some membrane proteins.
=== Bipolar disorder === Endoxifen is used to treat manic or mixed episodes associated with bipolar I disorder in India. It has been found that the endoxifen improves manic symptoms as well as mixed episode symptoms of patients with bipolar I disorder and has been considered an effective and well-tolerated treatment for this condition. Bipolar disorder is associated with overactive protein kinase C (PKC) intracellular signaling. To date, there have been three phases of clinical trials. And, in the phase III trials, endoxifen reduced the total Young Mania Rating Scale (YMRS) score from 33.1 to 17.8. A significant (p < 0.001) improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) score was observed for endoxifen (4.8 to 2.5). The endoxifen is well-tolerated by the subjects as depicted in the changes in Clinical Global Impression-Severity of Illness scores.
=== The renaissance: the hammerhead ribozyme and the group I intron: P4-6 === For a considerable time following the first tRNA structures, the field of RNA structure did not dramatically advance. The ability to study an RNA structure depended upon the potential to isolate the RNA target. This proved limiting to the field for many years, in part because other known targets—i.e., the ribosome—were significantly more difficult to isolate and crystallize. Further, because other interesting RNA targets had simply not been identified, or were not sufficiently understood to be deemed interesting, there was simply a lack of things to study structurally. As such, for some twenty years following the original publication of the tRNAPHE structure, the structures of only a handful of other RNA targets were solved, with almost all of these belonging to the transfer RNA family. This unfortunate lack of scope would eventually be overcome largely because of two major advancements in nucleic acid research: the identification of ribozymes, and the ability to produce them via in vitro transcription. Subsequent to Tom Cech's publication implicating the Tetrahymena group I intron as an autocatalytic ribozyme, and Sidney Altman's report of catalysis by ribonuclease P RNA, several other catalytic RNAs were identified in the late 1980s, including the hammerhead ribozyme. In 1994, McKay et al. published the structure of a 'hammerhead RNA-DNA ribozyme-inhibitor complex' at 2.6 Ångström resolution, in which the autocatalytic activity of the ribozyme was disrupted via binding to a DNA substrate.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.